International Clinical Trial: Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07530094) titled 'Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma' on April 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Ning Jiang, M.D./Ph.D.

Condition: Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Intervention: Biological: Camrelizumab

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: December 1, 2025

Target Sample Si...